Calendar

A Science & Innovation Webinar, presented by Abbvie.

Many patients require augmentation of their antidepressant with an additional therapy, and augmentation with an atypical antipsychotic is a guideline-recommended option for appropriate Major Depressive Disorder (MDD) patients. This session will focus on the burden of MDD and the impact of an atypical antipsychotic approved for the adjunctive treatment of MDD.

12-1pm ET

Unlocking the Value of Patient-Centered Research for Payer Decision Making

There is growing recognition that involving patients in health care research and decision-making can improve health care delivery and quality across a range of decision-making contexts. However, several uncertainties surrounding patient-centered research, including how payers use it, may undermine future investment. This can result in missed opportunities to engage patients in meaningful research and improve health outcomes. This session will examine the opportunities and challenges associated with generating and using patient-centered research from multiple stakeholder perspectives, including payers, researchers, and policymakers. It will also share key insights from a national effort to engage public and private payers in discussions about using patient-centered comparative clinical effectiveness research (CER) in their decision-making. In addition, actionable strategies will be presented for increasing the use and relevance of patient-centered research.  

2-3pm ET

Preparing for the Financial and Practical Impacts of Pharmaceutical Tariffs

Tariffs are dominating the front pages of newspapers and are at the top of mind for many Americans (and their wallets). Though prescription drugs have historically been excluded from tariffs, the threat to expand tariffs to the pharmaceutical supply chain has increased. This session will provide an overview of how tariffs work, the unique vulnerabilities of different aspects of the U.S. pharmaceutical supply chain to tariffs, and how manufacturers, payers, and providers are reacting to and managing the future risk of tariffs.  

4-5pm ET Satellite Symposium

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia with Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

Sponsored and presented by Pharmacy Times Continuing Education, separate registration required. Click here to register.

This activity is supported by an educational grant from Astrazeneca.

Hyperkalemia is an electrolyte disorder that can result in serious cardiac complications. It can occur in the inpatient or outpatient setting and is more likely to occur in patients with comorbidities such as chronic kidney disease heart failure, hypertension, diabetes, or other cardiovascular conditions especially when receiving renin-angiotensin-aldosterone system inhibitors. Hyperkalemia increases morbidity, mortality, and health care costs in these patient populations. Although potassium binders have been available for decades, traditional therapies such as sodium polystyrene sulfonate are limited by safety and tolerability concerns. Newer agents offer improved efficacy and safety profiles, making it essential for managed care pharmacists to understand their role in both acute and chronic hyperkalemia management. This activity will explore treatment options for acute and chronic hyperkalemia including real world use and practice patterns, identify the economic challenges associated with the condition, and review approaches to for developing cost-effective, patient-centered coverage policies. With a greater understanding of hyperkalemia and the treatment landscape, managed care pharmacists can expand patient access to appropriate treatments, maximize patient outcomes, and improve health care resource utilization.

A Science & Innovation Webinar, presented by Abbvie.

Vitiligo is more than a cosmetic concern. It is a chronic, autoimmune disease characterized by the progressive loss of melanocytes, leading to depigmented patches on the skin—the body’s most visible and socially expressive organ. NSV reflects underlying immune dysregulation and can be associated with systemic comorbidities such as autoimmune thyroid disease, type 1 diabetes, pernicious anemia, and alopecia areata. Beyond the physical manifestations, NSV carries a profound psychological burden, with increased rates of anxiety, depression, and social withdrawal. These interconnected challenges not only affect patient quality of life but also contribute to broader healthcare utilization and underscore the need for holistic, long-term management strategies.

An AMCP Member Webinar

A Science & Innovation Webinar, presented by Abbvie.

One of the primary goals of acute treatment of migraine is rapid and consistent freedom from pain and associated symptoms without recurrence. Regardless of migraine frequency or time of month, it is important that every appropriate person with migraine be offered a migraine-specific treatment. The objective for this webinar is to review the migraine disease state and outline the clinical data for an acute treatment of migraine including data for perimenstrual attacks.